Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 8:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Obesity With Diabetes Clear all
Recruiting Not applicable Interventional

Facilitated Transitions From Postpartum to Primary Care Coordination for People With Chronic Conditions

NCT06557005
View directory record Official record
Conditions
Hypertension, Diabetes, Postpartum, Pregnancy, Anxiety, Depression, Obesity
Interventions
Facilitated Transition to Primary Care
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
1,320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 28, 2026, 8:43 AM EDT
Completed Phase 2 Interventional Results available

ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or Type 2 Diabetes Mellitus (T2DM) and Suspected NAFLD

NCT02330549
View directory record Official record
Conditions
Prediabetic State, Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
Interventions
Cenicriviroc 150 mg, Placebo
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Fort Sam Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Sep 28, 2026, 8:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Mechanism Underlying Beta-cell Failure in Obese African Americans With History of Hyperglycemic Crises

NCT00753142
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Intralipid 20%, Glucose infusion
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Sep 28, 2026, 8:43 AM EDT
Active, not recruiting Phase 3 Interventional

VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

NCT07104383
View directory record Official record
Conditions
Weight Loss
Interventions
VK2735
Drug
Lead sponsor
Viking Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
125
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 110 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 28, 2026, 8:43 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Composition & Function of Sarcoplasmic Reticulum in Persons With the Metabolic Syndrome

NCT02122666
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
muscle biopsy
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 25, 2024 · Synced Sep 28, 2026, 8:43 AM EDT
Recruiting Not applicable Interventional

RESET System Pivotal Trial (Rev F)

NCT04101669
View directory record Official record
Conditions
Diabetes type2, Obesity
Interventions
RESET Liner, Sham
Device · Other
Lead sponsor
Morphic Medical Inc.
Industry
Eligibility
22 Years to 65 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Miami, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Sep 28, 2026, 8:43 AM EDT
Completed Not applicable Interventional Results available

Intervening in Diabetes With Healthy Eating, Activity, and Linkages To Healthcare - The I-D-HEALTH Study

NCT01435603
View directory record Official record
Conditions
Diabetes Mellitus, Hyperglycemia, Obesity, Glucose Metabolism Disorders, Metabolic Diseases, Endocrine System Diseases, Overnutrition, Nutrition Disorders, Overweight, Body Weight, Signs and Symptoms
Interventions
Standard Lifestyle Advice, Advice Plus Lifestyle Intervention
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Sep 28, 2026, 8:43 AM EDT
Completed Phase 3 Interventional

A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

NCT06066515
View directory record Official record
Conditions
Obesity
Interventions
survodutide, Placebo
Combination Product
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
726 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
32
States / cities
Phoenix, Arizona • Spring Valley, California • Walnut Creek, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 28, 2026, 8:43 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM

NCT06845202
View directory record Official record
Conditions
Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)
Interventions
ALN-4324, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
7
States / cities
Montclair, California • Washington D.C., District of Columbia • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 28, 2026, 8:43 AM EDT
Active, not recruiting Phase 3 Interventional

A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight

NCT06962280
View directory record Official record
Conditions
Type 1 Diabetes, Obesity, Overweight
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
18
States / cities
Bonita, California • Escondido, California • Newport Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 28, 2026, 8:43 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Research on the Nature, Diagnosis, and Treatment of Obesity and Diabetes

NCT00229268
View directory record Official record
Conditions
Insulin Resistance, Obesity
Interventions
Not listed
Lead sponsor
Rockefeller University
Other
Eligibility
21 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Sep 28, 2026, 8:43 AM EDT
Not yet recruiting Not applicable Interventional

ENLIGHT Trial: ESG With Fundal Mucosal Ablation

NCT07792226
View directory record Official record
Conditions
Obesity, Obesity (Body Mass Index >30 kg/m2)
Interventions
Endoscopic Sleeve Gastroplasty (ESG), Fundal Mucosal Ablation
Procedure
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 28, 2026, 8:43 AM EDT
Terminated Not applicable Interventional Results available

Exercise, Sleep Quality and Nocturnal Fat Oxidation in Metabolic Syndrome

NCT04105218
View directory record Official record
Conditions
Metabolic Syndrome, PreDiabetes, Hypertension, Obesity, Hyperlipidemias
Interventions
Exercise
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
19 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Sep 28, 2026, 8:43 AM EDT
Completed No phase listed Observational

Food Intake and Appetite in the Children of Mothers With Diabetes

NCT00339313
View directory record Official record
Conditions
Diabetes
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
7 Years to 10 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 28, 2026, 8:43 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist

NCT06851858
View directory record Official record
Conditions
Endocrinology, Diabetes, Type II, Obesity
Interventions
AZD6234, Placebo to match
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
18
States / cities
Birmingham, Alabama • Mobile, Alabama • Doral, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 28, 2026, 8:43 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)

NCT05874635
View directory record Official record
Conditions
Weight Loss, Metabolic Syndrome, Diabetes Mellitus, Type 2, Central Obesity, Insulin Resistance, Glucose Intolerance, Metabolic Glucose Disorders
Interventions
Continuous Glucose Monitor Device
Device
Lead sponsor
Signos Inc
Industry
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Sep 28, 2026, 8:43 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes

NCT01725126
View directory record Official record
Conditions
Obesity
Interventions
GSK2890457, Metformin, Placebo, Liraglutide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
3
States / cities
Chula Vista, California • Miami, Florida • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 28, 2026, 8:43 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Examination of the Anti-inflammatory and Insulin Sensitizing Properties of Doxycycline in Humans

NCT01375491
View directory record Official record
Conditions
Type 2 Diabetes, Obesity
Interventions
Doxycycline, Placebo
Drug · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 28, 2026, 8:43 AM EDT
Recruiting Phase 3 Interventional

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

NCT07794579
View directory record Official record
Conditions
Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal
Interventions
Orforglipron, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
2,001 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
80
States / cities
Anniston, Alabama • Birmingham, Alabama • Pelham, Alabama + 73 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 28, 2026, 8:43 AM EDT
Completed Not applicable Interventional Results available

Study of Gelesis100 on Body Weight in Overweight and Obese Subjects With and Without Type 2 Diabetes

NCT02307279
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Gelesis100, placebo
Device
Lead sponsor
Gelesis, Inc.
Industry
Eligibility
22 Years to 65 Years
Enrollment
436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
25
States / cities
Anaheim, California • San Diego, California • Tustin, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Sep 28, 2026, 8:43 AM EDT
Withdrawn Phase 4 Interventional

Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes

NCT02811484
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Exenatide-LAR plus Dapagliflozin placebo, Exenatide-LAR plus Dapagliflozin, Insulin Titration, Behavioral Therapy
Drug · Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 28, 2026, 8:43 AM EDT
Completed Phase 4 Interventional Results available

Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia

NCT00690235
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Diabetes, Weight Gain
Interventions
Pramlintide, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 28, 2026, 8:43 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

NCT07654374
View directory record Official record
Conditions
Obesity, Overweight, Chronic Weight Management, Type2 Diabetes Mellitus
Interventions
aleniglipron, Placebo
Drug
Lead sponsor
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
1,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
74
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 28, 2026, 8:43 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Semaglutide in CFRD

NCT05788965
View directory record Official record
Conditions
Cystic Fibrosis, Cystic Fibrosis-related Diabetes
Interventions
Semaglutide
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 28, 2026, 8:43 AM EDT